Oregon’s Licensed Psilocybin Centers Pass First Independent Safety Audit, but High Costs Raise Access Concerns

The first independent investigation into how Oregon’s regulated psilocybin service centers operate in practice has delivered a broadly reassuring verdict on safety, alongside a sobering warning about affordability. Researchers at Washington University School of Medicine in St. Louis and the University of Missouri found that licensed centers across the state consistently followed the screening and supervision requirements mandated by Oregon’s pioneering legal framework, offering the clearest picture yet of how the first regulated psilocybin program in the United States functions outside the laboratory. The study, published October 12 in Health Affairs Scholar, comes at a moment of intense national interest in psychedelic-assisted therapy, as lawmakers, clinicians and patients weigh whether the Oregon experiment should serve as a template for other states.

Oregon became the first state to legalize regulated, supervised psilocybin use in 2023, opening the door to a treatment built around the psychoactive compound found in so-called magic mushrooms. Since then, people experiencing depression, anxiety, post-traumatic stress disorder and substance use disorders have sought out the state’s licensed centers, drawn in part by clinical trial evidence suggesting that psilocybin, when combined with psychological support or psychotherapy, can produce meaningful relief for some patients. The drug remains illegal under federal law, which has made Oregon’s state-level regulatory experiment a singular case study in how psychedelic services might be delivered at scale. Until this new work, however, almost nothing was known about what prospective clients actually encounter when they contact a center, or what safeguards operate in real-world conditions rather than controlled trial settings.

To answer that question, the research team adopted a mystery shopper design, a method long used in health services research to evaluate how systems treat real patients. Three co-authors made scripted phone calls posing as potential clients who described depression along with either a personal history of alcohol use disorder or a family history of psychosis, details chosen because they are clinically relevant risk factors that responsible providers should probe. The callers documented whether staff asked about medications, suicidal ideation and psychiatric history, all of which are required elements of Oregon’s legal framework for psilocybin services. They also recorded the prices quoted for treatment. Of Oregon’s 22 active centers at the time, the team successfully reached 15 by phone, providing a substantial sample of the state’s operating facilities.

The results were striking in their consistency. No center allowed unsupervised or take-home use of psilocybin, a finding that directly counters fears that the state’s model might function like a retail dispensary. Staff at every center routinely asked about psychiatric history, current medications and contraindications before discussing next steps, and nearly every center flagged psychoactive medications that should not be combined with psilocybin. Critically, no center advised callers taking antidepressants to stop their medication without first consulting their primary care physician, a safeguard with real clinical importance given the risks of abrupt discontinuation and the pharmacological interactions that can complicate psychedelic therapy.

From a pharmacological standpoint, that caution is well founded. Psilocybin is a prodrug that is converted in the body to psilocin, which acts primarily as an agonist at the serotonin 2A receptor, the molecular trigger for the drug’s characteristic alterations in perception, mood and cognition. Combining psilocybin with certain psychiatric medications, particularly serotonergic drugs, can blunt or complicate its effects, and stopping antidepressants abruptly carries its own hazards, including discontinuation symptoms and relapse risk. The fact that facilitators consistently deferred medication decisions to prescribing physicians suggests that the state’s training and regulatory requirements are translating into behavior that aligns with mainstream psychiatric practice, not just psychedelic subculture norms.

The qualitative texture of the interactions impressed the researchers as much as the checklist compliance. Co-senior author Leopoldo J. Cabassa, a professor at Washington University’s Brown School who co-directs the university’s Center for Mental Health Services Research, described the calls as thoughtful conversations in which facilitators engaged callers, asked good questions and worked to gather as much information as possible before recommending services. In his telling, facilitators pushed past a simple checklist to genuinely understand a caller’s history. Co-senior author Kevin Xu, an assistant professor of psychiatry at WashU Medicine, admitted that the team had wondered going in whether Oregon’s model might operate like a dispensary in practice, allowing someone to call a center, pick up psilocybin and take it home with little screening along the way. Instead, he was surprised by how detailed the questions about mental health and risk factors turned out to be, and, he noted, by how expensive the services were.

That expense emerged as the study’s central caveat. The median cost of a supervised psilocybin session was $1,900, and not a single center accepted insurance, a combination that places treatment far beyond the reach of many Americans who might benefit from it. When the researchers later interviewed center staff, they learned that high operating and licensing costs make these services difficult to sustain for the centers themselves and difficult to afford for the people who seek them. The financial strain is visible in the program’s own numbers: of the 26 centers Oregon had licensed, four closed before the study’s calls even began, and another seven could not be reached by phone. First author Dani Adams, an assistant professor of social work at the University of Missouri who began the research as a postdoctoral fellow at WashU, pointed out that Oregon has dosed more people with psilocybin in a regulated model than anywhere else in the world, yet the treatment remains out of reach for most Americans struggling with their mental health.

The affordability problem carries particular weight for veterans, a population with elevated rates of PTSD, depression and suicide that has fueled bipartisan interest in getting psychedelic-assisted therapy approved by the U.S. Food and Drug Administration. Cabassa observed that in the absence of accessible, affordable regulated care at home, some veterans have instead sought unregulated treatments abroad, a trend that underscores what is at stake in getting domestic access right. The findings also complement a recent cohort study reporting that serious adverse reactions among 346 Oregon clients were uncommon, together building an early evidence base suggesting that the state’s safety architecture is holding up under real-world conditions even as its economic architecture struggles.

The study also reflects the broader maturation of psychedelic science at Washington University, where research has expanded from basic neuroscience to implementation. Co-author Ginger Nicol, a professor of psychiatry at WashU Medicine who co-directs the Center for Holistic Interdisciplinary Research in Psychedelics alongside Cabassa, was principal investigator on a landmark 2024 study published in Nature showing how psilocybin temporarily desynchronizes activity across the human brain, among the first investigations to map the drug’s effects at that scale. Nicol described the new study as an example of the university’s interdisciplinary approach to psychedelic science, noting that the team recognized an opportunity and moved quickly to collect data filling a major gap in scientific knowledge. With this work, she and Cabassa noted, WashU’s footprint in the field now spans everything from brain circuitry to the practical delivery of care.

The study, titled with the mystery shopper’s own framing question, was supported by National Institutes of Health grants along with institutional funding from Washington University, and the funders played no role in the design, conduct, analysis or publication of the research. Its implications reach well beyond Oregon’s borders. As other states consider following Oregon’s lead and as federal policymakers weigh FDA approval pathways for psychedelic therapies, the Oregon data offer the first empirical answer to a deceptively simple question: when a vulnerable person calls a psilocybin center, what actually happens? The answer, for now, is careful screening, supervised sessions and honest conversations, delivered at a price that the system has yet to solve. As Cabassa put it, the task ahead is to figure out what safeguards are needed and make sure they are maintained even as the system works to solve for accessibility, a balancing act that will define the next chapter of psychedelic medicine in America.

Subject of Research: Real-world safety screening and accessibility at Oregon's licensed psilocybin service centers

Article Title: Psilocybin providers follow safety guidelines, study finds

Article References: Psilocybin providers follow safety guidelines, study finds. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: psilocybin, Oregon, psychedelic-assisted therapy, mystery shopper study, mental health screening, Health Affairs Scholar, Washington University in St. Louis, treatment cost, depression, PTSD, drug policy, veterans